Global Crohn's Disease (CD) Market 2015-2019: Key Players are AbbVie, Astra Zeneca, Biogen Idec, Johnson & Johnson, Takeda Pharmaceutical & UCB

News provided by

Research and Markets

31 Mar, 2015, 16:51 GMT

DUBLIN, Mar. 30, 2015 /PRNewswire/ --Research and Markets

(http://www.researchandmarkets.com/research/xjm723/global_crohns) has announced the addition of the "Global Crohn's Disease (CD) Market 2015-2019" report to their offering.

Continue Reading
600769
600769
Research and Markets Logo. (PRNewsFoto/PR NEWSWIRE EUROPE)
Research and Markets Logo. (PRNewsFoto/PR NEWSWIRE EUROPE)

The analysts forecast the Global CD market to grow at a CAGR of 2.84% over the period 2014-2019.

CD is an ongoing condition that causes inflammation of the digestive tract or the GI tract. CD may also be named as ileitis, granulomatous enteritis or colitis, regional enteritis, or terminal ileitis. The exact etiology of CD is unknown. Usually, CD affects the small intestine and the beginning of the large intestine. However, the disease can disturb any part of the GI tract, from the mouth to the anus. CD can occur at any age; however, it is usually first diagnosed in people in their teens and twenties.

This report covers the present scenario and the growth prospects of the Global CD market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of CD. The Global CD market can be divided into five segments: 5-ASA, Antibiotics, Biologicals, Corticosteroids, and Immunomodulators.

An increase in strategic collaborations is one key trend being witnessed in the market. As a result of intense competition in the market, vendors are forming strategic alliances to increase their share in the market.

According to the report, the high prevalence of CD has led to an increase in the number of medical prescriptions to treat the disease. Globally, the incidence rate for CD varied from 0.30 to 16.50 cases per 100,000 people annually.

Further, the report states that the expiry of patents results in the loss of exclusivity leading to a rapid decline in the sales of that specific drug in the market. The expiry of patents of major drugs leads to the development of their generic forms resulting in a fragmented market.

Key Vendors

  • AbbVie
  • Astra Zeneca
  • Biogen Idec
  • Johnson & Johnson
  • Takeda Pharmaceutical
  • UCB

Other Prominent Vendors

  • Amgen
  • Boehringer Ingelheim
  • Celltrion
  • ChemoCentryx
  • Ferring Pharmaceuticals
  • Merck
  • Mitsubishi Tanabe
  • Novartis
  • Novo Nordisk
  • Pfizer

Key Topics Covered:

  1. Executive Summary
  2. List of Abbreviations
  3. Scope of the Report
  4. Market Research Methodology
  5. Introduction
  6. Disease Overview
  7. CD Pipeline Landscape
  8. Market Landscape
  9. Market Segmentation by Drug Class
  10. Geographical Segmentation
  11. Buying Criteria
  12. Market Growth Drivers
  13. Drivers and their Impact
  14. Market Challenges
  15. Impact of Drivers and Challenges
  16. Market Trends
  17. Trends and their Impact
  18. Vendor Landscape
  19. Key Vendor Analysis

For more information visit http://www.researchandmarkets.com/research/xjm723/global_crohns

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com